Time To Worry? Analysts Just Downgraded Their RxSight, Inc. (NASDAQ:RXST) Outlook

Market forces rained on the parade of RxSight, Inc. (NASDAQ:RXST) shareholders today, when the analysts downgraded their forecasts for this year. Revenue estimates were cut sharply as analysts signalled a weaker outlook - perhaps a sign that investors should temper their expectations as well.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

After the downgrade, the consensus from RxSight's eleven analysts is for revenues of US$134m in 2025, which would reflect a definite 10.0% decline in sales compared to the last year of performance. Prior to the latest estimates, the analysts were forecasting revenues of US$168m in 2025. The consensus view seems to have become more pessimistic on RxSight, noting the pretty serious reduction to revenue estimates in this update.

Check out our latest analysis for RxSight

The consensus price target fell 42% to US$12.22, with the analysts clearly less optimistic about RxSight's valuation following this update.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. These estimates imply that sales are expected to slow, with a forecast annualised revenue decline of 13% by the end of 2025. This indicates a significant reduction from annual growth of 51% over the last three years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 8.3% annually for the foreseeable future. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - RxSight is expected to lag the wider industry.

The Bottom Line

The most important thing to take away is that analysts cut their revenue estimates for this year. They're also anticipating slower revenue growth than the wider market. The consensus price target fell measurably, with analysts seemingly not reassured by recent business developments, leading to a lower estimate of RxSight's future valuation. Given the stark change in sentiment, we'd understand if investors became more cautious on RxSight after today.

Thirsting for more data? We have estimates for RxSight from its eleven analysts out until 2027, and you can see them free on our platform here.

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.